CLOs on the Move

Martek Biosciences Corporation

www.martek.com

 
Martek Biosciences Corporation is a Columbia, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

MAIA Biotechnology

MAIA Biotech is a targeted therapy, immuno-oncology company focused on the development and commercialization of first-in-class drugs

Engage Therapeutics

Engage Therapeutics was founded by Greg Mayes, President and CEO; and Jouko Isojarvi MD, PhD Executive Vice President and Chief Medical Officer. Engage`s founders bring a combination of strong biopharma pedigrees and personal, family connections to epilepsy. Greg’s son has epilepsy, while Jouko has spent his entire career taking care of epilepsy patients as well as developing and commercializing approved treatments for this condition.

Steakholder Foods

Meat. It’s an ancient and universal tradition. A story of human evolution and progress, family and culture. A story of our relationship with animals. With the

RedShift BioAnalytics Inc

RedShift BioAnalytics is developing powerful new analytical tools for the R&D, life science and biopharmaceutical markets. Our measurement solutions combine tunable lasers, microfluidics, and analytical technologies to achieve revolutionary improvements in performance and measurement capabilities. At RedShift, our mission is to provide customers with solutions that accelerate product discovery, development and manufacturing timelines while enabling dramatic improvements in performance, efficiency and cost.

Connectyx

Connectyx is a development-stage biomedical company focusing on novel treatments for rare diseases. In November, the Company announced it is changing its name to Curative Biotechnology, Inc. and has applied for the name change and a trading symbol (CURB) with the Financial Industry Regulatory Authority, Inc., which should take effect in the first quarter of 2021. Connectyx is focused on therapies with potentially accelerated development paths as a result of either the disease, the nature of the therapeutic itself, or the stage of clinical development. At the heart of the Company is a product development engine that rests on our unique S.O.A.R. filter (Science, Opportunity, Acceleration, Rare Disease.) At Connectyx, we envision a world where all patients have a therapeutic option.